BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Positioned to be at Center Stage of Neurological Diagnostics Space

Company: Brain Scientific Inc. (BRSF)
Category: Stock Spotlights

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears well-positioned to offer solutions for the growing market need in the post-pandemic world. “As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting,” reads a recent article. As such, the market for BRSF’s innovative products appears to expand. “It is becoming increasingly clear that neurological diagnostics will be at the center of the future post-COVID-19 health care of patients who suffered from the infection. As a commercial stage health care company focused on developing innovative medical devices and software disrupting the brain diagnostics market, Brain Scientific is poised to be at the center stage of neurological diagnostics space offering solutions for this growing public health problem with its two commercialized and FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM).”

To view the full article, visit https://ibn.fm/YTiKW

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050